EP Patent

EP4470537A1 — Compound for use in treating fibrodysplasia ossificans progressiva (fop)

Assigned to Queens University at Kingston · Expires 2024-12-04 · 1y expired

What this patent protects

The present invention relates to a compound for use in treating fibrodysplasia ossificans progressiva (FOP) in a human subject, wherein the compound is in accordance with the following formula:or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present invention relates to a compound for use in treating fibrodysplasia ossificans progressiva (FOP) in a human subject, wherein the compound is in accordance with the following formula:or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4470537A1
Jurisdiction
EP
Classification
—
Expires
2024-12-04
Drug substance claim
No
Drug product claim
No
Assignee
Queens University at Kingston
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.